Frontiers in Veterinary Science (Jun 2024)

Behavioral comorbidities treatment by fecal microbiota transplantation in canine epilepsy: a pilot study of a novel therapeutic approach

  • Antja Watanangura,
  • Antja Watanangura,
  • Antja Watanangura,
  • Sebastian Meller,
  • Nareed Farhat,
  • Jan S. Suchodolski,
  • Rachel Pilla,
  • Mohammad R. Khattab,
  • Bruna C. Lopes,
  • Andrea Bathen-Nöthen,
  • Andrea Fischer,
  • Kathrin Busch-Hahn,
  • Cornelia Flieshardt,
  • Martina Gramer,
  • Franziska Richter,
  • Franziska Richter,
  • Anna Zamansky,
  • Holger A. Volk,
  • Holger A. Volk

DOI
https://doi.org/10.3389/fvets.2024.1385469
Journal volume & issue
Vol. 11

Abstract

Read online

IntroductionAnxiety and cognitive dysfunction are frequent, difficult to treat and burdensome comorbidities in human and canine epilepsy. Fecal microbiota transplantation (FMT) has been shown to modulate behavior in rodent models by altering the gastrointestinal microbiota (GIM). This study aims to investigate the beneficial effects of FMT on behavioral comorbidities in a canine translational model of epilepsy.MethodsNine dogs with drug-resistant epilepsy (DRE) and behavioral comorbidities were recruited. The fecal donor had epilepsy with unremarkable behavior, which exhibited a complete response to phenobarbital, resulting in it being seizure-free long term. FMTs were performed three times, two weeks apart, and the dogs had follow-up visits at three and six months after FMTs. Comprehensive behavioral analysis, including formerly validated questionnaires and behavioral tests for attention deficit hyperactivity disorder (ADHD)- and fear- and anxiety-like behavior, as well as cognitive dysfunction, were conducted, followed by objective computational analysis. Blood samples were taken for the analysis of antiseizure drug (ASD) concentrations, hematology, and biochemistry. Urine neurotransmitter concentrations were measured. Fecal samples were subjected to analysis using shallow DNA shotgun sequencing, real-time polymerase chain reaction (qPCR)-based Dysbiosis Index (DI) assessment, and short-chain fatty acid (SCFA) quantification.ResultsFollowing FMT, the patients showed improvement in ADHD-like behavior, fear- and anxiety-like behavior, and quality of life. The excitatory neurotransmitters aspartate and glutamate were decreased, while the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and GABA/glutamate ratio were increased compared to baseline. Only minor taxonomic changes were observed, with a decrease in Firmicutes and a Blautia_A species, while a Ruminococcus species increased. Functional gene analysis, SCFA concentration, blood parameters, and ASD concentrations remained unchanged.DiscussionBehavioral comorbidities in canine IE could be alleviated by FMT. This study highlights FMT’s potential as a novel approach to improving behavioral comorbidities and enhancing the quality of life in canine patients with epilepsy.

Keywords